tbuckley/cabot-search huggingface dataset:
Sequential therapy with the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas: An Adult Brain Tumor Consortium phase I study (ABTC1101).
Authors: Matthias Holdhoff, Stuart A. Grossman, Jeffrey G. Supko, Xiaobu Ye, Joy D. Fisher, Serena Desideri, Richard L. Wahl, David Schiff
Journal: Journal of Clinical Oncology (2013)

TPS2105 Background: Despite recent advances in their treatment, high-grade gliomas (HGG) carry a dismal prognosis. Treatment options at recurrence are particularly limited and a re-challenge with temozolomide (TMZ) frequently appears as the most appropriate systemic treatment option in patients whose progression occurred off TMZ. This study investigates the sequential treatment of mibefradil (MIB), a selective Cav3 calcium channel blocker, and standard dose TMZ. Preclinical data showed that Cav3 inhibitors such as MIB can slow tumor growth without significant effect on normal tissues and can induce cell cycle arrest in cancer cells at the G1/S-phase checkpoint. We hypothesize that withdrawal of MIB could synchronize and release cells into S-phase, thereby potentiating the cytotoxic effect of TMZ. Methods: This trial is an open-label, multicenter phase I study, structured into a dose escalation phase to determine the maximum tolerated dose of MIB (MTD; Primary Objective) and an expansion cohort of 10 patients at the MTD level. Adults with recurrent HGG (WHO grade 3 or 4) who have previously received standard adjuvant therapy with radiation (RT) and TMZ (last dose ≥ 3 months prior to enrollment) and who have not received other cytotoxic therapy (except for carmustine wafers) are eligible. Patients receive oral MIB for 7 days on a 4 x/day (QID) schedule, followed by standard dose TMZ at 150-200 mg/m 2 for 5 days each 28-day cycle. Dose finding uses a modified 3+3 design, starting at MIB 25 mg po QID (100 mg/day) with dose increases of 25 mg/dose per dose level. The target dose-limiting toxicity (DLT) rate is ≤ 33%. Secondary Objectives: (1) safety and adverse event analysis (incl. cardiac monitoring during cycle 1), (2) pharmacokinetic profile of MIB, (3) response assessment (RANO criteria), and (4) assessment of the potential effect of MIB on tumor DNA synthesis as determined by fluorothymidine positron emission tomography (FLT PET; extension cohort). Enrollment status as of January 2013: cohort 1 completed without DLT; cohort 2 enrolling at MIB 200 mg/day. Clinical trial information: NCT01480050.
ACUTE CORONARY SYNDROME IN RETROVIRAL POSITIVE PATIENTS CHALLENGES AND DILEMMAS WITH SPECIAL EMPHASIS ON CORONARY REVASCULARIZATION
Authors: Natraj Setty, Nagaraja Moorthy, T.R. Raghu, B.C. Srinivas, K.H. Srinivas, I. Beeresh, Rangaraj Ramalingam, Jayashree Kharge, C.N. Manjunath
Journal: Journal of the American College of Cardiology (2017)
Regional cooling significantly reduces liposomal doxorubicin-induced palmar-plantar erythrodysesthesias (PPE) in patients with recurrent ovarian cancer
Authors: R. A. Sayer, S. Apte, S. S. Tedjarati
Journal: Journal of Clinical Oncology (2006)

18507 Objective: To evaluate the effect of regional cooling on the incidence and severity of liposomal doxorubicin-induced PPE in patients with recurrent ovarian cancer. Methods: Following IRB-approval, a retrospective chart review identified all patients treated with liposomal doxorubicin for recurrent ovarian cancer from 7/00 through 7/05. It was then determined whether patients received a regional cooling protocol, which involved placing hands and feet in ice water during chemotherapy infusion. Information was collected including patient demographics, prior chemotherapy, and grade and severity of PPE. Results: 73 women were treated for recurrent ovarian cancer with liposomal doxorubicin over the 5-year period. The median age was 58 years (range 24 to 82). The number of cycles ranged from 2 to 27 (median of 5). Liposomal doxorubicin dosages were available for 69 patients. Of the 69 patients, 4 patients were treated at 30 mg/m 2 , 64 patients were treated at 40mg/m 2 , and 1 patient was treated at 50mg/m 2 . The number of prior chemotherapy regimens ranged from 1 to 6 (median of 2.4) and the total number of all prior cycles ranged from 6 to 57 (median of 10). 25 of 73 patients (34%) were treated using the regional cooling protocol, while 48 of 73 (66%) were not. All incidences of PPE occurred in patients treated at the 40mg/m 2 dosing. The overall incidence of PPE in the regional cooling group was 24% compared to 54% in the non-regional cooling group (p = 0.0067). In the regional cooling group, 12% had grade 1 PPE, 8% had grade 2 PPE, 4% had grade 3, and none developed grade 4 PPE. Of the 48 patients without regional cooling, 19% had grade 1 PPE, 15% had grade 2 PPE, 15% had grade 3, and 2 of 4% had grade 4 PPE. Of the 25 patients receiving regional cooling, 1 patient (4%) required discontinuation of liposomal doxorubicin due to grade 3 PPE while 11 patients of the 48 patients who did not receive regional cooling (23%) required discontinuation due to PPE (p = 0.048). The incidence of PPE was not associated with age at diagnosis or total number of previous chemotherapy cycles. Conclusions: Regional cooling is effective in significantly reducing the incidence and severity of liposomal doxorubicin-induced PPE in patients with recurrent ovarian cancer. No significant financial relationships to disclose.
CONCOMITANT USE OF ANTIPLATELET AND ORAL ANTICOAGULATION AMONG PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE PROSPECTIVE SPRINT-AF REGISTRY
Authors: Milan Gupta, Yan Yan Wu, Mahesh Kajil, Michelle Tsigoulis, Jafna Cox, Paul Dorian, Carl Fournier, David Gladstone, Evan Lockwood, G.B. John Mancini, Ashfaq Shuaib, Narendra Singh, Andrew Ha
Journal: Journal of the American College of Cardiology (2017)
LEFT VENTRICULAR MECHANICAL PROPERTIES ASSESSED BY SINGLE BEAT METHOD IN EARLY STAGES OF DIASTOLIC DYSFUNCTION/HEART FAILURE WITH PRESERVED EJECTION FRACTION
Authors: Himanshu Gupta, Oleg F. Sharifov, Chun S. Schiros, Jose Tallaj, Inmaculada Aban, Sumanth Prabhu, Louis J. Dell'italia, Thomas Denney
Journal: Journal of the American College of Cardiology (2017)
Risk Adapted Treatment in Childhood Hodgkin's Lymphoma: Outcome and Changing Epidemiologic Features in 25 Years
Authors: Rejin Kebudi, Sema Bay Buyukkapu, Omer Gorgun, Fulya Yaman Agaoglu, Bulent Zulfikar, Inci Ayan, Ayca Iribas, Dizdar Yavuz, Oner Dogan, Emin Darendeliler
Journal: Blood (2016)
The Tetraspanin CD9 Regulates Engraftment and Mobilization of Human CD34+ Hematopoietic Stem/Progenitor Cells and Modulates VLA-4 Activity
Authors: Kam Tong Leung, Karen Li, Yorky Tsin Sik Wong, Kathy Yuen Yee Chan, Xiao-Bing Zhang, Alex Wing Kwan Leung, Tak Yeung Leung, Kam Sze Tsang, Pak Cheung Ng, Chi Kong Li
Journal: Blood (2015)
A historic disease still prevalent today
Authors: Lorne V Mitchell, Matthew R Wilson, Susan Holmes
Journal: BMJ (2017)

A 79 year old man was referred to the medical assessment unit by his general practitioner. Over the previous four weeks he had experienced progressive discolouration of both lower legs. His GP had given two courses of antibiotics for possible cellulitis but there was no clinical improvement.

He was systemically well and had no history of fever. He denied any trauma to the legs and had no dermatological history. He was taking no regular medication.

The man lived alone and was fully independent. His diet lacked fruit and vegetables.

On examination he had normal pulse, blood pressure, and oxygen saturations and no fever. Chest and abdominal examination were unremarkable. There was widespread bruising (ecchymosis) of the lower legs with “woody” oedema (fig 1⇓). Inspection of the legs more proximally revealed perifollicular haemorrhage and “corkscrew” hairs (fig 2⇓, fig 3⇓). The right leg appeared larger than the left but the calf was soft and non-tender.



Fig 1  Right lower leg





Fig 2  Skin changes above the right knee





Fig 3  Close-up of skin changes above the right knee



A coagulation screen, renal, and liver function tests were normal. Doppler ultrasound of the leg showed no evidence of deep vein thrombosis. Urinalysis was normal. …
Risk assessment model for haematologic toxicity (HT) in patients with solid tumours (ST) during the first chemotherapy (CT) cycle
Authors: A. M. Casas, J. Rifà, J. L. González Larriba, A. Carrato, A. López Pousa
Journal: Journal of Clinical Oncology (2006)

18516 Background: Bone marrow supression is the main type of CT dose-limiting toxicity. Specific studies on HT impact factors are key to help establish appropriate protocols in routine patient care. Objective: to identify significant factors among demographical and clinical variables for first-cycle CT-induced HT in patients (pts) with ST. Methods: Data was obtained from the Delfos Study, a multicentre prospective-cohort non-interventional study in Spain. To obtain a predictive model of logistic regression (LR), we followed the hierarchical principle as a way to ensure replication of results. This model was implemented for global HT, defined as compliance with at least one of the following criteria: anaemia grade (G) ≥2, thrombocytopenia G ≥2, neutropenia G ≥3, febrile neutropenia (FN, neutropenia G ≥3 and body Tª ≥38 Cº). A ROC curve was used to determine the best value for sensitivity and specificity of the model. Values were chosen so that both sensitivity and specificity resulted ≥70% and among the resulting possibilities, and due to study nature, the one providing higher specificity was taken. Results: A total of 1,194 pts with ST (breast, 37.9%; lung, 17.6%; colorectal, 15%; other, 29.5%) were included in 88 Spanish medical oncology health centres. Most pts were women (56%), mean age (SD) of 58(12) yrs. The LR model obtained predicted the global HT (p Chi-sq &lt; 0.0005), and includes the following factors: gender, tumour type, treatment intention, TNM-(T), TNM-(N), baseline haemoglobin (Hb), baseline lymphocyte count (LC), AST and the interaction gender-treatment intention. From those, five were statistically significant at the 0.05 level: baseline Hb (p &lt; 0.0005, OR = 0.555), baseline LC (p = 0.026, OR = 0.8), type of treatment intention -neoadjuvant- (p = 0.013, OR = 0.265), TNM-(N) (p = 0.008, OR = 1.261), and interaction gender-treatment intention (p = 0.014). Inherent sensitivity and specificity of the equation were, respectively, 71.9% and 75.8%. Conclusions: A risk prediction model for global first-cycle CT-induced HT in pts with ST in Spain was implemented. Five prediction factors were identified. Baseline Hb and LC, as well as neoadjuvant intention, were inversely associated with HT. Toxicity increased with the number of affected lymph nodes. No significant financial relationships to disclose.
COMBINED SERUM ALBUMIN AND C-RECTIVE PROTEIN LEVELS PREDICT LONG-TERM OUTCOMES IN PATIENTS WITH CORONARY ARTERY DISEASE AFTER A FIRST PERCUTANEOUS CORONARY INTERVENTION
Authors: Hideki Wada, Tomotaka Dohi, Katsumi Miyauchi, Shuta Tsuboi, Manabu Ogita, Takatoshi Kasai, Satoru Suwa, Hiroyuki Daida
Journal: Journal of the American College of Cardiology (2017)
PROGNOSTIC IMPORTANCE OF BLOOD PRESSURE AND HEART RATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: THE SUMMIT TRIAL
Authors: James Brian Byrd, David E. Newby, Julie A. Anderson, Peter M.A. Calverley, Bartolome R. Celli, Nicholas J. Cowans, Courtney Crim, Fernando J. Martinez, Jørgen Vestbo, Julie Yates, Robert D. Brook
Journal: Journal of the American College of Cardiology (2017)
MOST PATIENTS WITH ACUTE CORONARY SYNDROMES ARE ALREADY AT HIGH RISK PRIOR TO THE EVENT AND LIPID MANAGEMENT IS UNDERACHIEVED BOTH BEFORE AND AFTER HOSPITALIZATION: THE PHAETHON STUDY
Authors: Dimitrios Terentes-Printzios, Charalambos Vlachopoulos, George Andrikopoulos, Stylianos Tzeis, Efstathios Iliodromitis, Dimitri Richter, Athanasios Pipilis, Dimitrios Stakos, David Symeonidis, John Lekakis, Dimitris Tousoulis, Panagiotis Vardas
Journal: Journal of the American College of Cardiology (2017)
EARLY VERSUS DELAYED INVASIVE INTERVENTION FOR NON-ST SEGMENT ELEVATION MYOCARDIAL INFARCTION IN PATIENTS OLDER THAN 80 YEARS: A NATIONWIDE ANALYSIS
Authors: Alejandro Lemor, Abel Casso Dominguez, Shawn Lee, Carlos Gongora, Farid Gholitabar, Davendra Metha
Journal: Journal of the American College of Cardiology (2017)
INCIDENCE AND OUTCOMES OF EARLY LEFT VENTRICULAR THROMBUS FORMATION FOLLOWING ST-ELEVATION MYOCARDIAL INFARCTION TREATED WITH PRIMARY PERCUTANEOUS CORONARY INTERVENTION
Authors: Shafik Khoury, Sarit Carmon, Gilad Margolis, Gad Keren, Yacov Shacham
Journal: Journal of the American College of Cardiology (2017)
LONG-TERM OUTCOMES OF CHILDHOOD LEFT VENTRICULAR NON-COMPACTION: RESULTS FROM A NATIONAL POPULATION-BASED STUDY
Authors: William Shi, Piers Daubeney, Alan Nugent, Gary Sholler, Robert Justo, Jim Ramsay, Terry Robertson, Margarita Betancur, Andrew Davis, Steven Colan, Ingrid King, Robert Weintraub
Journal: Journal of the American College of Cardiology (2017)
Liposomal anthracyclines and ifosfamide in the first line treatment of advanced soft tissue sarcomas: A two cohort phase II study
Authors: J. M. Siehl, E. Thiel, A. Schmittel, G. Hütter, U. Keilholz
Journal: Journal of Clinical Oncology (2006)

9563 Objectives: The current first line standard chemotherapy for advanced soft-tissue sarcomas is the combination of doxorubicine and ifosfamide. Liposomal encapsulation is a strategy pursued to reduce toxicity and improve tumor uptake. There are so far only limited systematic data regarding the efficacy of liposomal anthracyclines in advanced soft-tissue sarcomas. We have previously reported on a phase II study with liposomal daunorubicine (L-Dauno) with ifosfamide, named IDx 1 . Here we report on an additional cohort of the phase II study using liposomal doxorubicine (L-Doxo). Methods: In a single-arm two cohort phase II study 55 patients with advanced soft-tissue sarcoma had received first line a maximum of 6 cycles (median 2 cycles) of ifosphamide (5 g/m 2 ) and in cohort 1 L-Dauno (100 mg/m 2 , 40 patients) or in cohort 2 the approximate equivalent of L-Doxo (75 mg/m 2 , 15 patients). Cycles were repeated every 4 weeks in absence of disease progression. Primary study endpoint was response rate. Results: The overall response rate was 25% (n = 14). In the L-Dauno group the results were as follows: CR 3% (n = 1), PR 29% (n = 10), SD 17% (n = 6), PD 37% (n = 13), NED or intermittent death 14% (n = 5), and in the L-Doxo group: PR 20% (n =3), SD 26% (n =4) and PD 53% (n = 8). Interestingly, all three liposarcoma patients (two in the L-Dauno group, one in the L-Doxo group) responded, whereas liposarcoma usually carries a poor response rate. For both combinations toxicity was similarly tolerable with short episodes of hematotoxicity (leucocyte nadir on day 9, platelet nadir on day 11), 11 febrile episodes, no grade 3 or 4 mucositis, no cardiac toxicity and 5 episodes of grade 2 acute ifosfamide-related CNS-toxicity. Based on the hematotoxicity kinetics, three weekly regimens appear feasible. Conclusion: The combination of liposomal anthracyclines and ifosfamide is a safe and effective first line regimen in the treatment for advanced soft tissue sarcoma. Further evaluation in a randomized trial will be pursued. The unexpected high responsiveness of liposarcoma warrants further phase II investigation. 1 Siehl JM et al. Cancer 2005. No significant financial relationships to disclose.
Model-based prediction of defective DNA mismatch repair using clinicopathological variables in stage II and III colon cancers
Authors: A. J. French, F. Sinicrope, N. R. Foster, S. N. Thibodeau, D. J. Sargent, M. J. O'Connell
Journal: Journal of Clinical Oncology (2009)

11093 Background: Defective DNA mismatch repair (MMR) results in microsatellite instability (MSI) and is detected in approximately 15% of sporadic colon cancers. MMR status has been shown to provide prognostic and predictive information in primary colon cancers. We sought to develop a model to predict MMR deficiency using clinically available data, and thereby facilitate patient selection for MMR or MSI testing. Methods: TNM stage II and III colon carcinomas (n= 982) were studied from six 5- fluorouracil-based adjuvant therapy trials conducted by the North Central Cancer Treatment Group. MMR status in tumors had been analyzed by MSI (using mono- and dinucleotide markers) or by immunohistochemistry for MMR proteins (hMLH1 and hMSH2). Logistic regression and a recursive partitioning and amalgamation (RPA) analysis was used to identify important predictive factors of MMR status. Factors explored included age, gender, histologic grade, tumor site, stage, lymph node metastases, and T-stage. Results: Defective MMR was found in147 (15%) cancers. Tumor site was the most important predictor of MMR status followed by histologic grade. Distal tumors had a low likelihood of defective MMR (3% rate overall; 13/468), whereas proximal tumors had a greater likelihood of defective MMR (26%; 130/506). For patients with proximal tumors, the addition of histologic grade and gender increased the prediction of defective MMR ( Table ). Using tumor site, histologic grade, and gender, the logistic regression model showed excellent discrimination (c- statistic = 0.81). Conclusions: Tumor site is an important predictor of defective MMR that is rare in distal and increased in proximal tumors. The combination of proximal site, poor differentiation, and female gender resulted in a 51% likelihood of defective MMR. Therefore, this model can facilitate the selection of sporadic colon cancers for MMR or MSI testing to enable its use in clinical decision-making. [Table: see text] No significant financial relationships to disclose.
PROGNOSTIC IMPLICATIONS OF EPICARDIAL FAT VOLUME QUANTIFICATION IN ACUTE PERICARDITIS
Authors: Alexis S. Antonopoulos, George Lazaros, Evangelos Oikonomou, Panagiotis Vasileiou, Evangelos Oikonomou, Evangelia Stroumpouli, Apostolos Karavidas, Charalambos Antoniades, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2017)
Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload
Authors: Marvin A. Konstam, Michael Kiernan, Arthur Chandler, Ravi Dhingra, Freny Vaghaiwalla Mody, Howard Eisen, W. Herbert Haught, Lynne Wagoner, Divya Gupta, Richard Patten, Paul Gordon, Kenneth Korr, Russell Fileccia, Susan J. Pressler, Douglas Gregory, Patricia Wedge, Douglas Dowling, Matthew Romeling, Jeremy M. Konstam, Joseph M. Massaro, James E. Udelson
Journal: Journal of the American College of Cardiology (2017)
INTEGRATING HYPEREMIC MYOCARDIAL BLOOD FLOW AND CORONARY FLOW RESERVE FOR PREDICTING CARDIOVASCULAR MORTALITY OUTCOMES IN PATIENTS WITH KNOWN OR SUSPECTED ISCHEMIC HEART DISEASE
Authors: Ankur Gupta, Viviany Taqueti, T.P. van de Hoef, Paco Bravo, Venkatesh Murthy, Sara Seidelmann, Tomas Vita, Navkaranbir Bajaj, Thomas Christensen, Michael Osborne, Victoria Morgan, Courtney Foster, Meagan Harrington, Jon Hainer, Ornella Rimoldi, Sharmila Dorbala, Ron Blankstein, Paolo Camici, Marcelo Di Carli
Journal: Journal of the American College of Cardiology (2017)
INFLUENCE OF BETA-BLOCKERS ON MORTALITY IN CHRONIC HEART FAILURE PATIENTS WITH ATRIAL FIBRILLATION: FINDINGS FROM THE GULF-SAFE
Authors: Charbel Abi Khalil, Rajvir Singh, Wafa Rashed, Adel Khalifa, Mohammad Zubaid, Jassim Al Suwaidi
Journal: Journal of the American College of Cardiology (2017)
Total marrow irradiation (TMI) with helical tomotherapy and peripheral blood progenitor cell rescue (PBPC) following high-dose melphalan (Mel) and PBPC as part of tandem autologous transplant (TAT) for patients with multiple myeloma.
Authors: George Somlo, An Liu, Timothy E. Schultheiss, Paul Henry Frankel, Ricardo Tomas Spielberger, Leslie Popplewell, Kenny Zhou, Donna Hawkins, Amrita Y. Krishnan, Firoozeh Sahebi, Pablo Miguel Parker, Stephen J. Forman, Jeffrey Y.C. Wong
Journal: Journal of Clinical Oncology (2015)

8581 Background: Ablative dose total body irradiation (TBI) of 800 cGy in combination with high-dose melphalan (MEL) was found to be too toxic. TMI, an image-guided targeted TBI using TomoTherapy intensity modulated radiotherapy , given as the sole ablative regimen for the second cycle (C) of TAT was tested in patients (pts) with stable (SD)/responsive MM, in a phase I-II trial. Here we provide long-term update on outcome. Methods: We enrolled pts with Durie-Salmon stages (DS) I-III MM in response or with SD, who were ≤ 70 years old and ≤ 18 months from diagnosis. Pts received MEL 200 mg/m2 and AT (C 1), and, after recovery, TMI (MTD : 1600 cGy) and AT (C 2) followed by maintenance with dexamethasone and an IMiD. Results: 54 pts started treatment (23 F/31M). The median age was 54 years (31-67). DS stages were:I (N = 4), II (N = 18), III (N = 32). 44 of the 54 pts received TMI (28 of 36 pts enrolled at the MTD received TMI). 10 pts did not receive TMI due to post-MEL toxicities or pt or doctor’s choice. The median time between MEL and TMI was 65 days (range 47-125). All pts engrafted. 9/54 (17%) experienced febrile neutropenia (FN) following MEL, and 8/44 (18%) experienced FN after TMI; less frequent grade 3 or 4 non-hematologic toxicities were similar between MEL and TMI. Best responses included CR (N = 22, of which 3 were in CR prior to MEL), very good partial response (VGPR, N = 8, of which 2 were in VGPR prior to MEL) and PR or SD (N = 14). Median follow-up of alive pts is 73 months (27-117). Second malignancies included 2 skin, 1 breast, 1 thyroid carcinoma, and 1 acute myeloid leukemia. In intent-to-treat analysis median PFS for the 54 pts is 52 months (95% CI 34.4-NR), and median OS is not reached. PFS and OS at 5 years is 43% (95% CI 31-59) and 66% (95% CI 54-81), respectively. For pts enrolled at 1600cGy, the PFS and OS at 5 years were 48% (34-69) and 73% (59-90). Conclusions: TMI of 1600 cGy is feasible following MEL in MM patients. The long-term safety and PFS/OS are encouraging, and further assessment of TMI is warranted. Clinical trial information: NCT00112827.
BACULOVIRUSES-MEDIATED SUPEROXIDE DISMUTASE GENE THERAPY INHIBITS SMOOTH MUSCLE CELL PROLIFERATION, MIGRATION, INFLAMMATION, AND REACTIVE OXYGEN SPECIES IN BALLOON-INJURED ARTERIES
Authors: Shoa-Lin Lin, Song-Tay Lee, Jwu-Lai Yeh, Yong-Jian Geng
Journal: Journal of the American College of Cardiology (2017)
SYNERGISTIC EFFECTS OF CORONARY CALCIFICATION AND INFLAMMATION ON RISKS FOR ADVERSE CARDIOVASCULAR EVENTS AFTER PCI: RESULTS FROM A LARGE SINGLE-CENTER REGISTRY
Authors: Shunsuke Aoi, Usman Baber, Jason Kovacic, Roxana Mehran, Melissa Aquino, George Dangas, Joseph Sweeny, Pooja Vijay, Srushti Shah, Pedro Moreno, Annapoorna Kini, Samin Sharma
Journal: Journal of the American College of Cardiology (2017)
Astarabine, a Pro-Drug of Cytarabine, Is Safe for Patients with Advanced Acute Leukemia. A Phase I/IIa Single Center Study in Relapsed/Refractory or Medically Unfit Patients
Authors: Tsila Zuckerman, Ruth Ben Yakar, Stela Gengrinovitch, Ron Hoffman, Israel Henig, Noa Lavi, Luiza Akria, Yishai Ofran, Olga Nudelman, Nuhad Haddad, Martin S Tallman, Jacob M. Rowe
Journal: Blood (2015)